Table 3. Treatment options for breast carcinoma in situ in China.
| Options | N | % |
|---|---|---|
| Surgery | ||
| Radical mastectomy | 7 | 4.90 |
| Modified radical mastectomy | 97 | 67.83 |
| Breast conservative surgery | 14 | 9.79 |
| Simple mastectomy | 12 | 8.39 |
| BCT+SLN biopsy | 7 | 4.90 |
| others | 6 | 4.20 |
| Radiotherapy | ||
| No | 117 | 81.25 |
| RT after BCT | 14 | 9.72 |
| RT after Radical/Modified radical mastectomy | 8 | 5.56 |
| unknown | 5 | 3.47 |
| Chemotherapy | ||
| No | 73 | 49.32 |
| Neoadjuvant chemotherapy | 7 | 4.73 |
| Adjuvant chemotherapy | 55 | 37.16 |
| Unknown | 13 | 8.79 |
| Endocrine therapy | ||
| Total | ||
| No | 64 | 44.76 |
| Yes | 63 | 44.06 |
| Unknown | 16 | 11.19 |
| Among ER/PR positive | ||
| No | 24 | 26.97 |
| Yes | 55 | 61.80 |
| Unknown | 10 | 11.24 |
| Anong ER&PR negative | ||
| No | 24 | 80.00 |
| Yes | 2 | 6.67 |
| Unkown | 4 | 13.33 |
| Among Pre-menopausal | ||
| SERM | 42 | 95.46 |
| AI | 2 | 4.54 |
| Among Post-menopausal | ||
| SERM | 12 | 54.54 |
| AI | 10 | 45.45 |
| Target-HER2 therapy | ||
| No | 122 | 85.31 |
| Unknown | 21 | 14.69 |
BCT, breast conservation therapy; SLNB, sentinel lymph node biopsy; RT, radiotherapy; SERM, selective estrogen receptor modular; AI, aromatase inhibitor.